In a pioneering fixed dose study, weekly insulin efsitora alfa achieves A1C reduction comparable to that of daily insulin.

Crestone, Inc. ("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection (CDI).

Aurinia Pharmaceuticals recently disclosed that the first participant has received the initial dose in a Phase 1a single ascending dose (SAD) clinical trial for AUR200.

Roche's fenebrutinib showed almost total reduction in disease activity and disability advancement for as long as 48 weeks in patients with relapsing multiple sclerosis.

Invivyd starts initial dosing in Phase 1 trial of VYD2311, a new monoclonal antibody for COVID-19, expanding on PEMGARDA™'s success.

Biogen Reports Encouraging Topline Results from Study on Higher Dose of Nusinersen, Demonstrating Notable Success in SMA Treatment.

9.2-9.8 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

OncoC4 Starts Phase 1 Trial Dosing First Patient with the New SIGLEC10 Checkpoint Inhibitor ONC-841 for Solid Tumors.

Grünenthal announced the acquisition of the American pharmaceutical manufacturer Valinor Pharma for $250 million in order to obtain the rights to Movantik (naloxegol).

Allyx Therapeutics has begun a new clinical trial for its key drug, ALX-001, administering it to the first patient to assess safety, pharmacokinetics, and potential therapeutic effects in Parkinson’s disease.

Zealand Pharma and Boehringer Ingelheim (BI) announced breakthrough clinical trial results for Survodutide, a novel drug targeting metabolic dysfunction-associated steatohepatitis (MASH).

Merck and EyeBio Announce Start of Phase 2b/3 Clinical Study for Restoret™ to Treat Diabetic Macular Edema.